Pioneering diabetes device offered at London hospital gives new solution for diabetic Emirati children with rare insulin skin allergy

taylor-aged-918 February 2018, Dubai UAE: Great Ormond Street Hospital for Children in London (GOSH) have successfully treated a British diabetic boy with a skin allergy to insulin thanks to a pioneering device which helps deliver insulin by bypassing the skin.

Taylor Banks, nine, from the UK is the fifth child in the world to be fitted with a device with delivers insulin directly to his abdomen so it does not come into contact with his skin.

Type 1 diabetes affects around 35 million people in the Middle East region, including around 61,000 children[1]. Allergies to insulin is rare, with an estimated incidence of <1% to 2.4% in insulin-treated diabetic patients, however the severity of skin reactions to insulin in this case were very unique[2].

The youngster was first diagnosed with type 1 diabetes – where the body’s immune system attacks and destroys the cells that produce insulin – when he was two. He was rushed to hospital unconscious and treated with insulin which treated his diabetes but prompted a severe allergic reaction to the drug.

Speaking on Taylor’s experience having an insulin allergy, Taylor’s mother Gema Westwell said, “Straight after taking the injections he would go into a trance-like state, he was like a zombie, unable to communicate and function. We switched Taylor to an insulin pump hoping it would help, but then he started breaking out with painful red welts all over his body. It was so upsetting because nothing we were trying to do was helping to take the pain away. These welts eventually turned into permanent areas of abnormally sunken skin, into which no insulin could be given.”

His symptoms worsened until the youngster was in constant pain and his parents had to check his sugar levels throughout the day and night to make sure he did not slip into unconsciousness.

When he was seven, doctors discovered his allergy to insulin was only skin deep, and he was referred to Great Ormond Street Hospital for children in London (GOSH), which treats over 1,500 children from the Middle East every year.

Dr Rakesh Amin, paediatric consultant in endocrinology at GOSH said, “Taylor’s quality of life was so poor and his prognosis so bleak that to not find a solution to this allergy was not an option.”

After a number of ideas were explored, earlier this year Dr Amin identified a device that connects an insulin pump device to the abdominal cavity, so the drug bypasses the skin, as a potential option to treat Taylor’s condition.

Last month, Taylor became the first child in the UK, and the fifth in the world, to be fitted with the device, GOSH said.

‘’This case nicely illustrates, that although we help manage children with common diabetes, the GOSH Diabetes Service particularly specialises in rare forms of diabetes or rare diabetes related complications. Our multidisciplinary team has unique skills sets and we try hard to find solutions using the latest technologies. We approach each child and young person as individuals, and aim to improve how each family is able to live with diabetes,” Dr Amin explains.

Taylor’s father Scott Banks concluded, “It’s still early days but we’ve already noticed the changes. Most importantly Taylor’s blood sugar levels are significantly lower and much more balanced. He isn’t in any pain, he hasn’t had any reaction in his skin and he’s sleeping better. For the first time Taylor identified on his own when he was having a hypo, which is just brilliant. This progression means everything to us. We’re so grateful to Dr Amin and GOSH and to all of the nurses and doctors who have helped Taylor. I just hope now that this will help him to have a chance at being a normal little boy, back in school and playing with his friends. He’s missed out on so much because he’s been so ill for so long, I hope this DiaPort will help Taylor get his childhood back.”

What are the signs of an allergic reaction to insulin?

  • Redness and pain at injection sites; either persistent or temporary
  • Groups of small bumps or swelling, similar to hives
  • Dents under the skin at injection sites which are often permanent

**Please note, Thumbay Group, Gulf Medical University, and HEALTH magazine are not liable nor responsible for the facts, figures, and overall content of the press releases on our portal.

Related Articles